Pharma channel feed

Yale Law School's free speech group says Boehringer's IRA ar­gu­ment is 'fun­da­men­tal­ly flawed'

Last year
Law

Court grants FTC in­junc­tion over IQVI­A's deal with Pro­pel Me­dia and Deep­In­tent

Last year
Marketing

Bey­for­tus ap­proved in Chi­na to pro­tect in­fants from RSV; Il­lu­mi­na in­vestor files class ac­tion suit

Last year

Cor­cept los­es patent fight with Te­va over Cush­ing's syn­drome drug

Last year
Law

Long­board stock soars on heels of pos­i­tive topline da­ta for seizure med­ica­tion

Last year
R&D

Omeza warned over poor man­u­fac­tur­ing con­di­tions; MiMedx in FDA talks over Ax­iofill re­clas­si­fi­ca­tion

Last year
Manufacturing

Mar­ket­ingRx roundup: Gilead, Pfiz­er spon­sor di­vas’ ben­e­fit con­cert; Am­gen joins Rose Pa­rade

Last year
Marketing

Brand drug nam­ing faces chal­lenges in emerg­ing cat­e­gories, ex­pert says

Last year
Marketing

Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

Last year
Deals
China

Sanofi, Re­gen­eron and Ab­b­Vie lead phar­ma TV ad­ver­tis­ers in boom­ing 2023

Last year
Marketing

No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

Last year
Deals
Cell/Gene Tx

Edge­wise boosts aware­ness of rare Beck­er mus­cu­lar dy­s­tro­phy as it pur­sues po­ten­tial first ther­a­py

Last year
Marketing

No­var­tis high­lights the pow­er of lan­guage in ‘My Can­cer, My Words’ cam­paign

Last year
Marketing

FDA seizes thou­sands of coun­ter­feit Ozem­pic units, warns con­sumers not to use

Last year
FDA+

Re­gen­eron scores Eylea patent win against My­lan, keep­ing biosim­i­lar at bay

Last year
Law

IRA like­ly to lead to high­er drug list prices and big­ger re­bates, Con­gres­sion­al Bud­get Of­fice pre­dicts

Last year
FDA+

Fol­low­ing FDA in­quiry in­to CAR-T safe­ty, agency adds warn­ing on sec­ondary can­cers for Carvyk­ti

Last year
FDA+

Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion

Last year
Deals

FDA ap­proves As­traZeneca, Ion­is' AT­TR drug as show­down with Al­ny­lam heats up

Last year
FDA+

Cal­lid­i­tas wins full ap­proval for steroid drug in rare au­toim­mune dis­ease

Last year
FDA+

Phar­ma com­pa­nies delist patents from FDA's Or­ange Book fol­low­ing FTC chal­lenges

Last year
FDA+

FDA find­ings at Mod­er­na's Mass­a­chu­setts fa­cil­i­ty don't re­flect qual­i­ty, safe­ty con­cerns, com­pa­ny says

Last year
FDA+
Manufacturing

Servi­er found guilty of fraud in tri­al over pulled weight loss drug Me­di­a­tor, re­vers­ing ear­li­er rul­ing

Last year
Law

Lil­ly part­ners with start­up Fau­na Bio to see if a squir­rel’s hi­ber­na­tion could lead to new obe­si­ty drugs

Last year
Startups
Deals
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times